The Cancer Stem-Like Cells (CSLCs) are cells with tumorigenic potential, which are involved in initiation, progression and spread of the tumor. Recent evidences in the last decade have suggested the existence of CSLCs in distinct types of tumors such as lung, brain, breast, prostate, colon, head and neck, ovarian and larynx cancers. They are identified by their tissue specific stem cell-like properties including self-renewal and having potential to differentiate.
Introduction
Laryngeal squamous cell carcinoma (LSCC), originating from laryngeal epithelial tissue, is one of the most commonly diagnosed malignancies in the head and neck region with an increased incidence rate in middle-aged and elderly men, worldwide (1, 2) . For early stage and localized LSCC, surgery, radiation, chemotherapy, and combination therapy are among the routine therapeutic techniques, however, radio-chemotherapy, the only therapeutic strategy for advanced and metastasized cases, has only limited effectiveness in treatment of late stage cancers. Despite considerable improvements in the laryngeal carcinoma treatment, which improved the quality of patients' life, the survival rates remained unchanged during more than three decades (3) . Therefore, novel and further efforts are required for complete understanding of mechanisms underlying laryngeal carcinogenesis and for development of more accurate and effective diagnostic, prognostic and therapeutic applications against LSCC.
Treatment failure stemming from primary or acquired resistance of advanced solid tumors, including laryngeal carcinoma was attributed to a small sub-population of cancer cells with tumorigenic potential; cancer stem like cells (CSLCs) (1) . Recent evidences in the last decade have suggested the existence of CSLCs in distinct types of tumors. They were considered as remaining after treatment and being responsible for the relapse of cancer. Comprehensive characterization of CSLCs and identification of CSLCs specific biomarkers will be of paramount importance for the development of novel strategies against cancer.
In this review, we have summarized the most current literature to understand the functions and roles of CSLCs in human LSCC. We believe that this review will contribute to knowledge of scientist not only working in laryngeal CSLCs research field, but also studying the CSLCs in other cancers and diseases, and will help elucidating the roles of CSLCs implicated in LSCC initiation, development, progression, and chemo-radioresistance.
Isolation and Characterization of Larynx Cancer Stem-like Cells
Tumors are proposed to be organized in a hierarchy of heterogeneous cell populations ranging from proliferative immature cells to various types of differentiated cell lineages (4) . The CSLCs, as also known as tumor initiating cells, were suggested as potentially tumorigenic, infiltrative and metastatic cells with intrinsic and/or acquired capacity of tumor initiation, progression, metastasis, chemoradioresistance and recurrence (5-7). Initially identified in hematopoietic cancers, the presence of CSLCs was demonstrated in a variety of tumors including LSCC (8-10). They were characterized by their stem cell-like properties including self-renewal, having potential to differentiate, expressing stem cell specific markers, and producing heterogeneous cancer population with different tumorigenic capacity (11) .
Although laryngeal CSLCs research is only in the initial stage, there have been several investigations providing insights into the true identification and characterization of larynx CSLCs (Figure 1 ). Luzar et al. provided the initial evidence for the existence of CSLCs in LSCC through demonstration of increased human telomerase reverse transcriptase (hTERT) expression in LSCC specimens (12) . hTERT was demonstrated to induce stemness characteristics and promote metastasis and recurrence in distinct cancer types (13) . Therefore, detection of hTERT overexpression might be evaluated as the first clue for involvement of CSLCs in the process of laryngeal carcinogenesis.
After identification of CD133, an apical plasma membrane protein with a molecular weight of 117 kDa, as a surface marker for isolation of stem cells from distinct tissues and tumors (4, 14) , Zhou et al. analyzed the expression status of CD133 in Hep2 Figure 1 -Laryngeal CSLCs are characterized by their stem cell-like properties including self-renewal and they carry distinct surface markers cells, a well characterized cell line used in LSCC research, and isolated CD133 positive cells to investigate their in vitro proliferation and differentiation ability (15) . CD133 positive cells constitute only a small population within the tumor. They have the potential to induce tumor formation in animal models even when injected as few as 100 cells (16, 17 Taking all these data into consideration, it is appropriate to suggest CD133, as a stem cell marker to isolate and characterize CSLCs in LSCC since CD133 enrichment has been shown to be associated with enhanced tumorigenic and proliferative potential both in vitro and in vivo (Figure 2) . Correlation of CD133 expression with stem cell specific markers strengthens its potential for utilization as a powerful tool in CSLCs research in LSCC.
As a result, true identification and isolation of CSLCs markers are important for better understanding of both CSLC biology and LSCC carcinogenesis. Their further characterization is necessary for development of novel therapeutic strategies particularly targeting CSLCs. Although there are several researches investigating the laryngeal CSLCs, more efforts are needed for further characterization of laryngeal CSLCs.
LSCC and Larynx Carcinogenesis
Tumor initiating cells have been confirmed to play critical roles in carcinogenesis process (7) . Characterization of tumor initiating CSLCs is carried out through their selection with surface markers and/or side population sorting. Recent studies demonstrated involvement of certain regulatory pathways, such as Wnt (27) , Notch (28), Hedgehog (29) and PI3K/Akt pathways (30) however, studies characterizing CSLCs of LSCC are limited.
As an initial study, Chen et al. explored the involvement of oncogenic BMI1 protein in acquisition of proliferative potential of laryngeal CSLCs. As a member of Polycomb group (PcG) proteins, BMI1 was demonstrated to be involved in gene silencing, through chromatin modifications (31) . Tumorigenic capacity of BMI1 has been shown in a variety of cancers, and it has been shown to play a role in normal stem cell proliferation (32) . BMI1 also has been shown to induce tumor invasion, metastasis and chemoresistance of solid tumors (33, 34) . Chen et al. demonstrated elevated expression of BMI1 in both laryngeal tumor tissues and CD133 positive Hep-2 cells, which provided maintenance of cell proliferation and prevented apoptosis. More importantly they showed that BMI1 was coexpressed with CD133 in LSCC specimens. Gene expression analysis pointed that BMI1 had a repressive influence on distinct tumor suppressor pathways including p53, p16, and PTEN. They suggested BMI1 as a molecular target to treat patients with LSCC (32).
Li et al investigated the expression of p75 neurotrophin receptor p75NTR (also known as CD271) and its possible functions in LSCC (35) . P75NTR has been initially described as a neural crest stem cell marker. A significant connection has been found between CSLCs and p75NTR expression, especially in cancers including melanoma, squamous cell carcinoma, and breast cancer (36) . Li et al. All these findings indicate the involvement of CD133 positive cells in LSCC carcinogenesis (Figure 2 ) and help shedding light into the mechanisms in which CSLCs might contribute to the LSCC pathogenesis (Figure 3) , however, the current data about the roles and functions of CSLCs in the pathogenesis of LSCC is limited, and further studies are required for clear understanding of this process. Unraveling the underlying mechanisms of LSCC carcinogenesis will also contribute to the knowledge of cancer biology and help scientists studying on other types of cancer.
CSLCs and Larynx Cancer Prognosis
Although LSCC is a prevalent cancer among men, there are still no currently available accurate and reliable prognostic tools with high specificity and sensitivity. Histo-pathological properties of the laryngeal tumors are utilized during clinical Considering the small number of attempts to find prognostic predictors in LSCC, it is clear that there is still an enormous need for identification of successful and reliable biomarkers for estimation of patients' clinical outcome.
CSLCs and Larynx Cancer Metastasis
Metastasis comprised about 90 % of deaths stemming from all human neoplasms and it was mostly associated with malignant progression of tumors. In 2015, around 13.560 new cases are estimated to be diagnosed with LSCC in the US (47) with an average rate of 19% metastasis (48) .
Tumor metastasis is a multistep process, in which several factors are involved. It simply starts with the initial invasion of the surrounding tissue, and continues with translocation of cancer cells through bloodstream to distant organs and adaption to the foreign microenvironment, where cells can proliferate and induce formation of macroscopic secondary tumors (49) . Epithelial-mesenchymal transition (EMT) process, which is dissolution of epithelial tight junctions and reduction of intercellular adhesion during morphologic alteration from polarized epithelial cell to mesenchymal cell phenotype, induces invasion and metastasis of tumors. Downregulation of epithelial markers such as E-cadherin, -catenin, and β-catenin and upregulation of mesenchymal markers such as Ncadherin, Vimentin, and Fibronectin results in loss of cell adhesion and cell-cell contact (50).
Downregulation of E-cadherin and upregulation of Vimentin levels resulted in increased metastasis and migration of tumor cells in head and neck squamous cell carcinoma (HNSCC) (51) . It has been reported that overexpression of hypoxia-inducible factor-1α (HIF-1α) protein was associated with metastasis and local recurrence in LSCC, proposing a descriptive role for HIF-1α in the malignant progression of LSCC (52) . Co-expression of HIF-1α with EMT markers Twist and Snail was also associated with metastatic progression in primary HNSCCs (53) . In addition, overexpression of TWIST, a transcription factor inducing EMT, was associated with increased cell motility, invasion, migration capacity in Hep-2 cells by reducing level of E-cadherin and initiation of N-cadherin expression (50).
Co-expression of CSLC markers with EMT markers has been demonstrated in various cancers. For example, N-cadherin and CD133 expressions were shown to be strongly correlated in both primary and recurred/metastasized breast cancer samples (54) . However, to our knowledge there is no currently available data about the correlation of EMT and CSLC markers in LSCC, which remains to be elucidated in further studies.
As to the relationship of CSLC markers to metastasis, CD133 expression demonstrated a strong significant association with patients exhibiting progressive lung cancer. Elevated expression levels of CSLC markers including CD133, CD44, and ALDH1 in primary prostate cancer have been linked to aggressive and invasive tumors (55) . CD133 is also reported to be significantly linked with invasion and metastasis of lung cancer (56) , pointing the possible involvement of CD133 positive laryngeal CSLCs. Furthermore, recently, Yang et al. showed that SOX2 overexpression had a critical role in induction of invasion and metastasis in LSCC patients. SOX2, a well-characterized transcription factor involved in maintenance of embryonic and neural stem cells, stimulated EMT process, in which tumor cells penetrate the lymphatic or blood vessels through involvement of WNT/β-catenin pathway (57) . Similarly, upregulated expression of p53, in addition to downregulated expression of CD44H and CD44v6 were associated with decreased survival. Among these markers, downregulated expression of CD44H also correlated with metastasis risk in LSCC (58). 
Interestingly

CSLCs and Larynx Cancer Therapy
Chemotherapy and radiotherapy are among the traditional treatment options for laryngeal cancer (62) . However, the radiation and chemotherapy resistance of laryngeal cancer cells remains to be an important problem to be solved. CSLCs have been implied in development of resistance to chemo-radio therapy in many types of malignancies and distinct signaling pathways have been demonstrated to be activated in CSLCs during this process.
Recent studies have suggested CSLCs as essential players in LSCC initiation, progression, recurrence, metastasis and resistance to chemotherapy and radiation. Yang et al. investigated chemoresistance of CD133 positive cells in laryngeal CSLCs and found that these cells exhibited more resistance to chemotherapy (63) . In addition, they demonstrated correlation of resistance with higher expression of ABCG2 (63) , which is a member of the human ATP Binding Cassette Family. Suer et al. also demonstrated upregulation of ABCG2 in CD133 positive LSCC cells (11) . ABCG2 is known to contribute to chemoresistance capability and stem cell characteristics of tumor cells. Its overexpression has been shown in many cancer types including LSCC (64, 65) . Besides, ABCG2 was demonstrated to be significantly upregulated in CSLCs following treatment with chemotherapeutics (66) . Therefore, increased ABCG2 expression in the isolated CD133 positive cells strengthened the idea that these cells are among the strong candidates for chemoresistance and recurrence of cancer (Figure 2 CSLCs are comprised of therapy resistant cells and targeting of these cells is necessary for development of more effective therapies to prevent metastasis in human cancers, including LSCC. However, since both normal and cancerous tissue specific stem cells share similar expressional and antigenic profiles, it is difficult to target specifically CSLCs (71) . Therefore, further studies in LSCC, as well as in other cancer types, are needed to find novel and specific biomarkers to distinguish CSLCs from normal stem cells.
LCSC and Future Perspectives
Although there have been important improvements recently on cancer diagnosis and therapy, LSCC still remains to be one of the leading causes of cancer deaths among men. For especially late stage LSCC cases, treatment strategies commonly fail to give positive clinical outcome, which necessitates understanding the underlying mechanisms of LSCC carcinogenesis and developing novel therapy tools based on the enlightened pathogenic processes.
Although CD133 is proposed as an effective surface molecule for isolation of laryngeal CSLCs, additional biomarkers are needed for true identification and characterization of CSLCs, which will provide the opportunity to determine appropriate gene and miRNA expression signatures associated with these cells through utilization of oligonucleotide microarray technologies, qRT-PCR, and similar methods. Analysis of specific signaling pathways involved in acquisition and maintenance of CSLC properties implicated in pathologic processes will let the discovery of new drugs for treating LSCC and development of novel therapeutic strategies with the help of further studies needed in this field.
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